Veracyte, Inc.
Veracyte, Inc. (Nasdaq: VCYT) is a global diagnostics company that develops and provides molecular tests to help clinicians make cancer diagnosis, prognosis and treatment decisions. Its U.S. tests are performed through its CLIA-certified laboratories, while international customers, including laboratories and… From the company’s description.
In fiscal 2025, Veracyte, Inc. reported revenue of $517.14M, up 16.0% from fiscal 2024, and net income of $66.35M. Its operating margin was 11.2%, and operations generated $136.31M in cash. Over the twelve months to Jun 30, 2026, revenue was $561.90M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Veracyte, Inc. does
In the company’s own words
Veracyte, Inc. (Nasdaq: VCYT) is a global diagnostics company that develops and provides molecular tests to help clinicians make cancer diagnosis, prognosis and treatment decisions. Its U.S. tests are performed through its CLIA-certified laboratories, while international customers, including laboratories and hospitals, can perform its in vitro diagnostic tests locally. Its portfolio includes Decipher Prostate and Decipher Bladder genomic classifiers, Afirma testing for thyroid nodules, the Prosigna breast cancer assay and the Percepta Nasal Swab test for assessing lung cancer risk in patients with lung nodules. Most revenue comes from Decipher Prostate and Afirma testing. The company also develops TrueMRD, a minimal residual disease testing platform, and acquired C2i Genomics in 2024 to add whole-genome MRD capabilities. Prosigna is distributed internationally as an in vitro diagnostic test, and the company is developing additional tests for decentralized use on laboratory platforms. Its U.S. testing revenue comes from government and commercial payers, while international in vitro diagnostic sales are made to laboratories and hospitals.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1384101
- SIC
- 8071
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Veracyte, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Veracyte, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Veracyte, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Veracyte, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Veracyte, Inc.'s last four quarterly filings that the numbers alone won't show?”